About 40%-50% of AML patients have a normal karyotype of leukemic cells, and one-half of these patients have mutations of nucleophosmin (NPM1)[8,9], which encodes a shuttle protein transporting continuously between the nucleus and cytoplasm [10]. This evidence concerns the gene NPM1 and acute myeloid leukemia.